Goldschmidt R A, Victor T A
Department of Pathology and Laboratory Medicine, Evanston Hospital, IL 60201, USA.
Semin Surg Oncol. 1996 Sep-Oct;12(5):314-20. doi: 10.1002/(SICI)1098-2388(199609/10)12:5<314::AID-SSU5>3.0.CO;2-G.
Lobular carcinoma in situ (LCIS) of the breast is commonly identified as an incidental finding in breast biopsies performed because of either a mammographic abnormality or a palpable mass. Although long recognized as an entity, the significance and optimal treatment of LCIS remains controversial. Initially regarded as a pre-invasive form of breast cancer analogous to ductal carcinoma in situ (DCIS), LCIS was treated by mastectomy. As evidence mounted for an equal risk of invasive carcinoma in both breasts, bilateral mastectomy was advocated by some. More recent studies suggest that LCIS is a marker for increased risk rather than a true precursor of invasive carcinoma, and this allows a more conservative approach. The pathologic aspects and natural history of LCIS are discussed.
乳腺小叶原位癌（LCIS）通常是在因乳腺钼靶异常或可触及肿块而进行的乳腺活检中偶然发现的。尽管LCIS早就被确认为一种疾病实体，但其意义和最佳治疗方法仍存在争议。LCIS最初被视为类似于导管原位癌（DCIS）的乳腺癌癌前形式，曾采用乳房切除术进行治疗。随着越来越多的证据表明双侧乳房发生浸润性癌的风险相同，一些人主张进行双侧乳房切除术。最近的研究表明，LCIS是风险增加的一个标志物，而非浸润性癌的真正前驱病变，这使得可以采取更为保守的方法。本文将讨论LCIS的病理特征和自然病程。
